JB Chemicals & Pharmaceuticals Ltd. (JB Pharma), one of the fastest growing pharmaceutical companies in India, announced its financial results for the quarter ended 30th September, 2023.

JB Pharma recorded revenue of Rs. 882 crores in the second quarter of FY24 registering growth of 9% from Rs. 809 crores in Q2 FY23. Operating EBITDA (Earnings before Interest Depreciation and Taxes) improved by 24% to Rs. 251 crores. Profit after Taxes registered strong growth of 36% to Rs. 151 crores vs Rs. 111 crores in Q2 FY23.

Commenting on the financial results, Nikhil Chopra, CEO and Wholetime Director, JB Pharma mentioned, “During Q2, the business delivered a healthy blend of domestic and international business growth, with expansion in domestic business led by our chronic segment and acquired portfolio. Our transformed go-to-market framework is driving gains in market share and improvement in our rankings in IPM. Our acquired portfolio has not only helped us increase our chronic segment presence and market rankings. but it is also beginning to positively impact our operating margins. We have made significant progress in the cardiology segment. Our domestic business showed strong resilience even during a period when the acute segment had relatively softer demand.

“International business has performed well, with sustained traction in our CDMO segment. International formulations have shown strong growth outside South Africa, as we focus on being agile to market needs and scaling up with new launches in the medium and long term. We are excited about the growth ahead and remain focused on strong execution to deliver as per plan across both domestic and international markets.”

For the first half of the financial year 2023-24, JB Pharma recorded revenue of Rs. 1778 crores as compared to Rs. 1594 crores, registering growth of 12%. Operating EBITDA (Earnings Before Interest Depreciation and Taxes) increased by 26% to Rs. 494 crores as compared to Rs. 392 crores. Profit after Tax registered strong growth of 36% to Rs. 293 crores vs INR 216 crores in H1 FY23.